YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
[short sale] abluecup As October begins, investors are keeping a close eye on heavily shorted stocks that could see heightened volatility. The latest mid- to mega-cap screen shows 39 stocks with short interest above 20% of shares outstandi…
Investing.com -- Raymond James has updated its Healthcare Top Picks list for October, adding three new stocks while removing others from the monthly selection. The firm added Xencor, Calyxt, and UnitedHealth Group to replace Relay Therapeu…
Recursion Pharmaceuticals RXRX continues to leverage its AI-native drug discovery platform through a broad portfolio of pharma, technology and data partnerships. These collaborations are expanding its pipeline while generating non-dilutive…
Recursion Pharmaceuticals RXRX uses an AI-driven drug discovery platform, Recursion Operating System (OS), to identify and develop novel therapies across its pipeline. It is advancing several clinical-stage programs, with REC-4881 emerging…
Thomas Catinazzo, Chief Financial Officer of Relay Therapeutics (NASDAQ:RLAY), sold 17,717 shares of common stock on Aug. 14, 2026, according to a SEC Form 4 filing. Transaction summary Metric Value Transaction value $349,734 Shares sold 1…
After skyrocketing 1,027% off a low, Relay Therapeutics taps AI and machine learning to fuel more gains. Continue Reading
For Immediate Release Chicago, IL – August 18, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial m…
Artificial intelligence (AI) is poised to reshape pharmaceutical research by addressing some of the industry's most persistent challenges: lengthy timelines, high development costs and substantial clinical failure rates. Traditional drug d…
Stock exchange financial or forex graph by Bigc Studio via Shutterstock Relay Therapeutics (RLAY) is a clinical-stage precision medicines company focused on targeted oncology, with a $4.4 billion market cap. RLAY has surged 486% over the p…
Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine-sensitive patients expected to initiate in early 2027, subject to regulatory feedback Presented initial positive clini…
Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.16 per share a year ago. These figures are adjusted…
CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and gen…
Key Points Thomas Catinazzo sold 187,163 shares of Common Stock for $3.18 million on June 22, 2026, at a weighted average price of around $16.97 per share. This transaction reduced his direct Common Stock holdings by 51.33%, leaving 177,46…
Relay Therapeutics Inc. (NASDAQ:RLAY) is one of the 10 best AI driven biotech stocks to invest in. On May 20, JonesResearch updated its coverage on Relay Therapeutics Inc. (NASDAQ:RLAY) after reviewing encouraging initial data for its drug…
[Genetic research and Biotech science Concept. Human Biology and pharmaceutical technology] jittawit.21 What are the most attractive biotech stocks right now for investors? Seeking Alpha analysts Stephen Ayers [https://seekingalpha.com/aut…
Relay Therapeutics(NASDAQ: RLAY) is a clinical-stage biotech company focused on cancers and genetic diseases, using a computational platform to identify small-molecule therapies. Relay's stock is up more than 344% over the past year, and i…
Key Points Relay had its initial public offering in 2020. The company's lead therapy is being tested for the treatment of vascular disorders and cancers. The company has plenty of cash to develop its therapies.10 stocks we like better than…
(RTTNews) - Relay Therapeutics, Inc. (RLAY), a clinical-stage, small-molecule precision medicine company, priced its public offering of 22.92 million shares of common stock at a public offering price of $12 per share. The gross proceeds fr…
CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and gene…
One trading session after Relay Therapeutics(NASDAQ: RLAY) announced positive results for an investigational treatment, its shares rocketed higher on Wednesday. That rally, which saw the biotech stock rocket almost 8% higher, was aided in…
Healthcare stocks rose Tuesday afternoon, with the NYSE Healthcare Index adding 1.1% and the State S PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
The S&P 500 Index ($SPX) (SPY) today is down -0.68%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.34%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.95%. June E-mini S&P futures (ESM26) are down -0.75%, and June E-mini Nas…
The S&P 500 Index ($SPX) (SPY) today is down -0.35%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.19%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.45%. June E-mini S&P futures (ESM26) are down -0.40%, and June E-mini Nas…
The S&P 500 Index ($SPX) (SPY) today is down -0.68%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.34%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.95%. June E-mini S&P futures (ESM26) are down -0.75%, and June E-mini Nas…
The S&P 500 Index ($SPX) (SPY) today is down -0.35%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.19%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.45%. June E-mini S&P futures (ESM26) are down -0.40%, and June E-mini Nas…
SB Investment Advisers (UK) Ltd reported a sale of 2,168,884 shares of Vir Biotechnology(NASDAQ:VIR) in its May 15, 2026, SEC filing, an estimated $17.28 million trade based on quarterly average pricing. What happened According to an SEC f…
Relay Therapeutics, Inc. (NASDAQ:RLAY) is one of the 10 Best Biotech Stocks to Invest In According to Billionaire Steve Cohen. On April 29, 2026, H.C. Wainwright hiked Relay Therapeutics, Inc. (NASDAQ:RLAY)’ price target from $19 to $25. I…
Quick Read All three biotechs have dense 2026 clinical and regulatory milestone calendars that can drive outsized share movements, with cash runways stretching into 2028-2029 and strong analyst support despite pre-revenue status and binary…
Relay Therapeutics Inc. (NASDAQ:RLAY) is one of the 10 Stocks Reeling From Huge Losses. Relay Therapeutics dropped for a second day on Tuesday, slashing 12.84 percent to finish at $13.03 apiece, as investors appeared to have taken profits…
Relay Therapeutics, Inc. Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline development Compelling efficacy and tolerability data for zovegalisib triplet in median 3L patients 44% ORR in heavily pre-treated, CDK4/6-e…
[Heart Health Concept] Eoneren/E+ via Getty Images As the market moves into the second week of Q1 earnings, we look at the most overbought stocks in the healthcare sector. Below is a list of the top 10 healthcare stocks ranked based on the…
Relay Therapeutics, Inc. (NASDAQ:RLAY) is one of the best low priced biotech stocks to invest in. On April 13, JonesResearch initiated coverage of Relay Therapeutics, Inc. (NASDAQ:RLAY) with a Hold rating and $18 price target. The firm sta…
Nextech Invest, Ltd. disclosed in a February 17, 2026, Securities and Exchange Commission (SEC) filing that it reduced its stake in Kymera Therapeutics(NASDAQ:KYMR) by 62,013 shares, an estimated $4.19 million trade based on quarterly aver…
Relay Therapeutics, Inc. (RLAY) shares ended the last trading session 5.4% higher at $10.69. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 17.2…
LAS VEGAS, March 2, 2026 /PRNewswire/ -- The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology ap…
We came across a bullish thesis on Erasca, Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on ERAS. Erasca, Inc.'s share was trading at $12.39 as of February 19th.Cidara (CDTX) Climbs 105% on $…